Preclinical models are developed to test lead compounds for toxicity and efficacy. This report 1) explores novel preclinical models (in vivo, in vitro, in silico, and systems biology) that show promise to expedite and improve the target validation, lead optimization, and toxicity screening timelines, and 2) discusses the various advantages and disadvantages of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) screening techniques. In addition, the report provides an outlook for preclinical testing over the next decade. It focuses on more than 60 companies that are involved in using or developing ADMET technologies to advance preclinical research and provides an update on how new models and systems have been employed to accelerate the discovery and development process.
Scope of this report
• Understand the basis of ADMET testing and why it is a necessary and important component of preclinical research
• Up-to-date information on the preclinical models and systems currently used in drug discovery and development.
• Evaluation of the key recent developments and activities of companies who are developing and licensing new ADMET technologies.
• Identification of existing models and how new ones are being developed to improve productivity and knowledge.
Source: Business Insights